Drug Profile
Research programme: monoclonal T cell receptors - Immunocore/AstraZeneca
Alternative Names: ImmTACs - Immunocore/AstraZenecaLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Immunocore; MedImmune
- Developer AstraZeneca; Immunocore
- Class Monoclonal antibodies; Proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in USA
- 05 Sep 2018 Early stage development is ongoing USA and United Kingdom (Immunocore Pipeline, September 2018)